Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Galera Therapeutics (GRTX) announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented at the 2022 ASCO Annual Meeting from June 3-7, 2022, in Chicago, Illinois.

Rhea-AI Summary

Galera Therapeutics (GRTX) announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented at the 2022 ASCO Annual Meeting from June 3-7, 2022, in Chicago, Illinois.

The oral presentation, led by Dr. Carryn M. Anderson, is titled 'ROMAN: Phase 3 trial of avasopasem manganese for severe oral mucositis in patients receiving chemoradiotherapy for locally advanced head and neck cancer.' The abstract number is 6005.

Additionally, the Phase 2 GRECO-2 study of rucosopasem will also be included in a poster session on June 4, 2022.

Argus Session date unavailable

-5.35% session move Open Argus

Details

News Market Reaction – GRTX

The recorded move for GRTX in the trading session of this news was -5.35%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago, Illinois.

Oral Presentation

Title: ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC)
Abstract Number: 6005
Presenter: Carryn M. Anderson, M.D., University of Iowa Hospitals & Clinics
Session Title: Head and Neck Cancer
Session Date and Time: Friday, June 3, 2022 | 2:45 p.m. – 5:45 p.m. CDT

Galera’s Phase 2 GRECO-2 study of rucosopasem (GC4711) in combination with stereotactic body radiation therapy in pancreatic cancer will also be presented at the ASCO meeting in a Trials in Progress poster session.

Poster Presentation

Title: GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer
Abstract Number: TPS4184
Presenter: Sarah Hoffe, M.D., H. Lee Moffitt Cancer Center
Session Title: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: Saturday, June 4, 2022 | 8:00 a.m. – 11:00 a.m. CDT

The titles of the abstracts are currently available in the ASCO digital program, with the full abstracts scheduled to be published on May 26, 2022, at 5 p.m. EDT.

About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (GC4419, also referred to as avasopasem) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com

William Windham
Solebury Trout
646-378-2946
wwindham@soleburytrout.com

Media Contact:
Zara Lockshin
Solebury Trout
330-417-6250
zlockshin@soleburytrout.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Galera Therapeutics' Phase 3 ROMAN trial?

The Phase 3 ROMAN trial evaluates the efficacy of avasopasem for treating severe oral mucositis in patients undergoing chemoradiotherapy for locally advanced head and neck cancer.

When and where will the clinical data from the ROMAN trial be presented?

The clinical data will be presented at the 2022 ASCO Annual Meeting from June 3-7, 2022, in Chicago, Illinois.

Who is presenting the ROMAN trial data at ASCO 2022?

Dr. Carryn M. Anderson from the University of Iowa Hospitals & Clinics will present the data.

What is the title of the oral presentation for the ROMAN trial?

'ROMAN: Phase 3 trial of avasopasem manganese for severe oral mucositis in patients receiving chemoradiotherapy for locally advanced head and neck cancer' is the title of the presentation.

What other study is Galera Therapeutics presenting at ASCO 2022?

Galera will also present the Phase 2 GRECO-2 study of rucosopasem in combination with stereotactic body radiation therapy for pancreatic cancer.

What are the abstract numbers for the presentations at ASCO 2022?

The abstract number for the ROMAN trial is 6005 and for the GRECO-2 study is TPS4184.